Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CVM Cel Sci Corp
- Stocks
- Healthcare
- NYSEAMERICAN: CVM
Price (delayed)
$2.1
Market cap
$6.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$12.3
Enterprise value
$12.65M
CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients
Highlights
The company's EPS rose by 35% YoY and by 15% QoQ
CVM's debt is down by 17% year-on-year and by 5% since the previous quarter
Cel Sci's quick ratio has decreased by 49% YoY and by 39% from the previous quarter
The equity has decreased by 44% YoY and by 29% from the previous quarter
Key stats
What are the main financial stats of CVM
Market
Valuations
Earnings
Shares outstanding
3.03M
Market cap
$6.37M
Enterprise value
$12.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$26.08M
Net income
-$27.27M
EBIT
-$26.56M
EBITDA
-$22.62M
Free cash flow
-$17.98M
Per share
Balance sheet
Liquidity
EPS
-$12.3
EPS diluted
-$12.3
Free cash flow per share
-$6.4
Book value per share
$3.11
Revenue per share
$0
TBVPS
$7.71
Total assets
$21.81M
Total liabilities
$13.81M
Debt
$10.53M
Equity
$8M
Working capital
-$2.48M
Debt to equity
1.32
Current ratio
0.55
Quick ratio
0.77
Net debt/EBITDA
-0.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-110.7%
Return on equity
-268.4%
Return on invested capital
-105%
Return on capital employed
-162.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CVM stock price
How has the Cel Sci stock price performed over time
Intraday
-11.02%
1 week
-16.33%
1 month
-75.86%
1 year
-94.21%
YTD
-82.5%
QTD
-69.61%
Financial performance
How have Cel Sci's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.08M
Net income
-$27.27M
Gross margin
N/A
Net margin
N/A
Cel Sci's operating income has increased by 11% YoY and by 2.5% from the previous quarter
CVM's net income is up by 9% year-on-year and by 2.4% since the previous quarter
Price vs fundamentals
How does CVM's price correlate with its fundamentals
Growth
What is Cel Sci's growth rate over time
Valuation
What is Cel Sci stock price valuation
P/E
N/A
P/B
0.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 35% YoY and by 15% QoQ
The stock's price to book (P/B) is 92% less than its 5-year quarterly average of 8.9 and 84% less than its last 4 quarters average of 4.2
The equity has decreased by 44% YoY and by 29% from the previous quarter
Efficiency
How efficient is Cel Sci business performance
CVM's return on equity is down by 23% year-on-year and by 13% since the previous quarter
Cel Sci's return on invested capital has decreased by 13% YoY and by 4.7% QoQ
The return on assets has declined by 12% year-on-year and by 6% since the previous quarter
Dividends
What is CVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CVM.
Financial health
How did Cel Sci financials performed over time
The total assets is 58% more than the total liabilities
Cel Sci's current ratio has plunged by 67% YoY and by 49% from the previous quarter
Cel Sci's quick ratio has decreased by 49% YoY and by 39% from the previous quarter
CVM's debt is 32% greater than its equity
The company's debt to equity has surged by 50% YoY and by 35% QoQ
The equity has decreased by 44% YoY and by 29% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.